


Remarks

Claims 1-69 are pending in the application. In response to a restriction requirement, Applicants elected Claims 1-44, 49, 50, 57 and 58 (Group I) drawn to compounds, compositions and methods of using the compounds of Formula (I). In response to Examiner's request for an elected species, Applicants hereby provisionally elect the compound of Example 2B having the following structure.



N-(Cyclopropylmethyl)-N'-[4-[2-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]-2-methylpropyl]phenyl]-sulfamide (2B) See, page 52 of the specification.

Claims 45-48, 51-52, 54-56, and 59-69 have been cancelled as being drawn to non-elected subject matter as a result of a restriction requirement (Group II claims directed to complex compositions and methods of use thereof and Group III claims directed to a kit). Applicants reserve the right to file one or more divisional applications to acquire rights to the restricted subject matter.

Applicants respectfully request reconsideration of the withdrawal of Claim 53 in light of the amendment to Claim 53 as presented above. Claim 53 as presently amended is dependent from Claims 49 and 50 which are part of the Group I claims. By deleting the reference to Claims 51 and 52, amended Claim 53 is no longer directed to methods of using complex compositions (Group II). Therefore, amended Claim 53 would be more appropriately examined with the Group I claims.

Date: May 7, 2004

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

Respectfully Submitted:

Arlene K. Musser
Arlene K. Musser
Attorney for Applicants
Registration No. 37,895